Share on StockTwits

Dendreon (NASDAQ:DNDN) was the target of a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 43,262,434 shares, a growth of 3.8% from the June 13th total of 41,667,933 shares, Analyst Ratings Net reports. Based on an average daily trading volume, of 2,320,206 shares, the short-interest ratio is currently 18.6 days. Currently, 28.2% of the shares of the company are sold short.

A number of research firms have recently commented on DNDN. Analysts at Zacks reiterated a “neutral” rating on shares of Dendreon in a research note on Tuesday, May 13th. They now have a $2.25 price target on the stock. Separately, analysts at Citigroup Inc. reiterated a “sell” rating on shares of Dendreon in a research note on Friday, May 9th. They now have a $2.00 price target on the stock, down previously from $3.00. Finally, analysts at Maxim Group downgraded shares of Dendreon from a “buy” rating to a “hold” rating in a research note on Thursday, May 8th. They now have a $1.00 price target on the stock, down previously from $4.00. Seven analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $2.83.

Dendreon (NASDAQ:DNDN) opened at 2.17 on Wednesday. Dendreon has a 52-week low of $1.81 and a 52-week high of $5.38. The stock’s 50-day moving average is $2.15 and its 200-day moving average is $2.62. The company’s market cap is $336.6 million.

Dendreon (NASDAQ:DNDN) last announced its earnings results on Thursday, May 8th. The company reported ($0.24) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.28) by $0.04. The company had revenue of $68.70 million for the quarter, compared to the consensus estimate of $69.19 million. During the same quarter last year, the company posted ($0.48) earnings per share. Dendreon’s revenue was up 1.8% compared to the same quarter last year. On average, analysts predict that Dendreon will post $-0.78 earnings per share for the current fiscal year.

Dendreon Corporation (NASDAQ:DNDN) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.